19:15 , Jul 20, 2018 |  BC Week In Review  |  Financial News

Provention raises $64M IPO

Autoimmune and infectious disease company Provention Bio Inc. (NASDAQ:PRVB) raised $63.9 million on July 19 through the sale of 16 million shares at $4 in an IPO underwritten by MDB Capital Group and Dougherty &...
00:15 , Jul 20, 2018 |  BC Extra  |  Financial News

Provention raises $64M IPO

Autoimmune and infectious disease company Provention Bio Inc. (NASDAQ:PRVB) raised $63.9 million on Thursday through the sale of 16 million shares at $4 in an IPO underwritten by MDB Capital Group and Dougherty & Co....
18:08 , May 11, 2018 |  BC Week In Review  |  Financial News

Provention plans IPO, reveals MacroGenics deal

Autoimmune and infectious disease company Provention Bio Inc. (Lebanon, N.J.) proposed on May 9 to raise up to $50 million in an IPO underwritten by MDB Capital Group. The company's pipeline includes several candidates in-licensed...
20:14 , May 10, 2018 |  BC Extra  |  Financial News

Provention plans IPO, reveals MacroGenics deal

Autoimmune and infectious disease company Provention Bio Inc. (Lebanon, N.J.) proposed to raise up to $50 million in an IPO underwritten by MDB Capital Group. The company's pipeline includes several candidates in-licensed from other companies...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Company News

MacroGenics, Takeda deal

Takeda terminated its option agreement and returned rights to bispecific antibody MGD010 to MacroGenics. The companies said the decision was not related to an ongoing Phase I trial of the candidate to treat autoimmune...
07:00 , Sep 12, 2016 |  BC Extra  |  Company News

Takeda throws DART back to MacroGenics

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) terminated its option agreement and returned rights to bispecific antibody MGD010 to MacroGenics Inc. (NASDAQ:MGNX). The companies said the decision was not related to an ongoing Phase I study of...
07:00 , Mar 23, 2015 |  BC Week In Review  |  Clinical News

MGD010: Phase I started

MacroGenics began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending doses of IV MGD010 in about 48 healthy volunteers. The start triggered a $3 million milestone payment to MacroGenics from Takeda...
04:11 , Dec 23, 2014 |  BC Extra  |  Company News

MacroGenics, Janssen enter DART deal

MacroGenics Inc. (NASDAQ:MGNX) climbed $4.05 (12%) to $38.58 after announcing it will receive $125 million up front in a deal granting the Janssen unit of Johnson & Johnson (NYSE:JNJ) exclusive worldwide rights to preclinical compound...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Company News

MacroGenics, Takeda deal

MacroGenics granted Takeda an option to license exclusive, worldwide rights to four research programs against undisclosed jointly selected targets. The products will be developed using MacroGenics' Dual-Affinity Re-Targeting (DART) technology. Takeda will fund R&D and...
03:26 , Oct 1, 2014 |  BC Extra  |  Company News

MacroGenics, Takeda announce second DART deal

MacroGenics Inc. (NASDAQ:MGNX) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) an option to license exclusive, worldwide rights to four programs against undisclosed jointly selected targets. The products will be developed using MacroGenics' Dual-Affinity Re-Targeting (DART) technology....